HUTCHMED Stock Forecast, Price & News

-0.83 (-1.99 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume412,223 shs
Average Volume327,197 shs
Market Capitalization$7.09 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.



HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. HUTCHMED (China) Limited has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.46 out of 5 stars

Medical Sector

992nd out of 2,214 stocks

Pharmaceutical Preparations Industry

477th out of 869 stocks

Analyst Opinion: 1.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

HUTCHMED (NASDAQ:HCM) Frequently Asked Questions

Is HUTCHMED a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HUTCHMED stock.
View analyst ratings for HUTCHMED
or view top-rated stocks.

What stocks does MarketBeat like better than HUTCHMED?

Wall Street analysts have given HUTCHMED a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but HUTCHMED wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting HUTCHMED?

HUTCHMED saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,870,000 shares, an increase of 102.6% from the June 15th total of 922,800 shares. Based on an average daily volume of 407,000 shares, the short-interest ratio is presently 4.6 days. Approximately 1.3% of the company's shares are sold short.
View HUTCHMED's Short Interest

How has HUTCHMED's stock been impacted by Coronavirus (COVID-19)?

HUTCHMED's stock was trading at $23.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HCM shares have increased by 77.9% and is now trading at $40.98.
View which stocks have been most impacted by COVID-19

What price target have analysts set for HCM?

3 Wall Street analysts have issued 12 month target prices for HUTCHMED's shares. Their forecasts range from $40.00 to $45.00. On average, they expect HUTCHMED's stock price to reach $42.50 in the next year. This suggests a possible upside of 3.7% from the stock's current price.
View analysts' price targets for HUTCHMED
or view top-rated stocks among Wall Street analysts.

Who are HUTCHMED's key executives?

HUTCHMED's management team includes the following people:
  • Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA, Exec. Chairman (Age 69, Pay $80k)
  • Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA, CEO & Exec. Director (Age 55, Pay $1.41M)
  • Mr. Johnny Cheng C.A., BEc, CA, CFO & Exec. Director (Age 54, Pay $788.96k)
  • Dr. Wei-Guo Su B.Sc., Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 64, Pay $1.21M)
  • Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, MA, EdM, Solicito, Company Sec. & Non-Exec. Director (Age 69, Pay $70k)
  • Mr. Mark Lee, Sr. VP of Corp. Fin. & Devel. (Age 44)
  • Mr. Charles Nixon, Group Gen. Counsel
  • Mr. Andrew Shih, Sr. VP of HR - Organization & Leadership Devel.
  • Dr. May Wang, Sr. VP of Bus. Devel. & Strategic Alliances (Age 58)
  • Mr. Hong Chen, Chief Commercial Officer - China, GM - Hutchison Sinopharm & GM - Hutchison Healthcare (Age 51)

Who are some of HUTCHMED's key competitors?

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).


(HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHMED's stock symbol?

HUTCHMED trades on the NASDAQ under the ticker symbol "HCM."

How do I buy shares of HUTCHMED?

Shares of HCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately $40.98.

How much money does HUTCHMED make?

HUTCHMED has a market capitalization of $7.09 billion and generates $227.98 million in revenue each year. The company earns $-125,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does HUTCHMED have?

HUTCHMED employs 1,280 workers across the globe.

What is HUTCHMED's official website?

The official website for HUTCHMED is

Where are HUTCHMED's headquarters?


How can I contact HUTCHMED?

HUTCHMED's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company can be reached via phone at 852-2121-3888 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.